title: Double phase CT during hepatic arteriography for diagnosis of hepatocellular carcinoma.
abstract: OBJECTIVE
  The purpose of this study is to assess the diagnostic impact of double phase computed tomography during hepatic arteriography for hepatocellular carcinoma.
  
  
  METHODS
  118 hepatocellular carcinomas in 73 cirrhotic patients who underwent double phase computed tomography during hepatic arteriography were enrolled in this study. Double phase computed tomography during hepatic arteriography consisted of computed tomography images obtained at 5-10 s (first phase) and 40-50 s (second phase) after the initiation of an intraarterial administration of 40-60 ml of contrast medium through the hepatic artery. Diagnostic accuracy of the first phase computed tomography during hepatic arteriography alone and double phase computed tomography during hepatic arteriography images for hepatocellular carcinoma were separately analyzed by three blinded readers independently. Alternative-free response receiver operating characteristic curves were constructed to compare each set of computed tomography during hepatic arteriography images.
  
  
  RESULTS
  The detection sensitivity of the double phase CTHA for HCC (mean, 83.1%) was significantly higher than that of the first phase CTHA alone (mean, 73.4%) (P < 0.01). Moreover, the positive predictive value of the double phase CTHA (mean, 93.7%) was higher than that of the first phase CTHA alone (87.4%). The area under the AFROC curve (Az value) of the double phase CTHA (mean, 0.88) was significantly higher than that of the first phase CTHA alone (mean, 0.77) (P < 0.05).
  
  
  CONCLUSIONS
  Double phase computed tomography during hepatic arteriography can improve the diagnostic accuracy of hepatocellular carcinoma.
authors.affiliation: Department of Radiology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. murakami@radiol.med.osaka-u.ac.jp
authors.forename: Takamichi
authors.initials: T
authors.lastname: Murakami
authors.forename: Manabu
authors.initials: M
authors.lastname: Takamura
authors.forename: Tonsok
authors.initials: T
authors.lastname: Kim
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Hori
authors.forename: Michael P
authors.initials: MP
authors.lastname: Federle
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Onishi
authors.forename: Kaname
authors.initials: K
authors.lastname: Tomoda
authors.forename: Hironobu
authors.initials: H
authors.lastname: Nakamura
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis*; D003287:Contrast Media / Q000008:administration & dosage; D005260:Female; D006499:Hepatic Artery / Q000000981:diagnostic imaging*; D006801:Humans; D007479:Iopamidol; D008113:Liver Neoplasms / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D015588:Observer Variation; D011237:Predictive Value of Tests; D012372:ROC Curve; D011856:Radiographic Image Enhancement / Q000379:methods*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D003287:Contrast Media; D007479:Iopamidol